DoxyPrEP shows major reductions in STIs: studies
From PositivelyAware.com…
Troy Grennan, MD, MSc, a clinical associate professor at the University of British Columbia, shared findings of a randomized controlled trial that studied the efficacy, tolerability, and use patterns of doxyPrEP. The trial included 52 men who have sex with men, all living with HIV and having a history of syphilis, in Toronto and Vancouver, Canada. The men were randomized to receive either a daily dose (100mg) of doxycycline or a placebo. Adherence was measured through blood tests to measure the amount of doxycycline, and researchers concluded nearly 80 percent took the medication throughout the trial period.
The outcomes were significant and in line with studies showing the efficacy of doxyPEP. Among the 41 (78.8%) participants who finished the 48-week study, there was a 79% reduction in syphilis, a 92% reduction in chlamydia and a 68% reduction in gonorrhea in the doxycycline arm compared to the placebo arm. The trial controlled for any differences in drug adherence or sexual behaviors. Three participants developed resistance to doxycycline, but Brennan said that because the number of people who developed resistance was small, it was hard to draw any definitive conclusions.